Zegocractin

Zegocractin
Identifiers
  • N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC19H11ClF3N3O3
Molar mass421.76 g·mol−1
3D model (JSmol)
  • CC1=C(C(=CC=C1)F)C(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3Cl)OC(O4)(F)F
  • InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27)
  • Key:QQMKTHUGOQDEIL-UHFFFAOYSA-N

Zegocractin (development code CM-4620) is a drug which acts as a selective inhibitor of the calcium channel ORAI1. It inhibits store-operated calcium entry (SOCE) and has anti-inflammatory effects. It is being researched for the treatment of pancreatitis, including acute pancreatitis associated with systemic inflammatory response syndrome (completed phase 2b CARPO trial).

References

  1. ↑ Waldron RT, Chen Y, Pham H, Go A, Su HY, Hu C, et al. (June 2019). "The Orai Ca2+ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis". The Journal of Physiology. 597 (12): 3085–3105. doi:10.1113/JP277856. PMC 6582954. PMID 31050811.
  2. ↑ Sutton R, Garg PK, Miller J, Kumar SS, Buxbaum JL, Philip M, Zhang J, Stauderman K, Hebbar S, Wu BU, Peacock WF, Gardner TB. "Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial". eClinicalMedicine. 93 103757. doi:10.1016/j.eclinm.2026.103757.